Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 c-Lecta Launches GMP-Grade Version of Denarase High Salt | Contract Pharma
Breaking News

c-Lecta Launches GMP-Grade Version of Denarase High Salt

Efficiently and cost-effectively removes nucleic acids in biomanufacturing processes that benefit from elevated salt levels.

c-LEcta, an international supplier of enzymes for the biopharmaceutical industry, has launched the GMP-grade version of Denarase High Salt, a strategic extension of its Denarase portfolio.

The GMP-grade version of Denarase High Salt is intended to serve customers with clinical and commercial stage processes that require compliance with the highest quality standards.

Denarase High Salt is utilized for the removal of DNA/RNA impurities in biopharmaceutical production. It is an engineered version of c-LEcta’s top-selling product Denarase and was designed for improved salt and pH tolerance, enabling customers more flexibility in process development.

The launch of Denarase High Salt GMP-grade marks a significant milestone in c-LEcta’s commitment to providing innovative solutions for the biopharmaceutical industry. This engineered enzyme efficiently and cost-effectively removes nucleic acids in biomanufacturing processes that benefit from elevated salt levels. Key applications include: 

  • Viral Vectors for Cell & Gene Therapies 
  • Viral Vaccines 
  • Viscosity reduction in Lysates 
  • Sample preparation in Electrophoresis and Chromatography

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters